Literature DB >> 26801361

[Pulmonary alterations in Hodgkin lymphoma].

Ádám Jóna1, Árpád Illés1, Katalin Szemes1, Zsófia Miltényi1.   

Abstract

Most of Hodgkin lymphoma patients survive due to combined chemo/radiotherapy. Improved survival brings long-term side effects to the front, which may determine the patients' subsequent quality of life and expected lifetime. This manuscript aims to analyze lung manifestations of Hodgkin lymphoma and treatment related pulmonary complications, demonstrated with own cases. The lung involvement in Hodgkin lymphoma is often secondary, and primary pulmonary involvement is very rare. The authors found 8-12% of lung involvement among their patients. Side effects of treatment consist of pulmonary infections in conjuction with immunosuppression, while on the other hand bleomycin and chest irradiation as part of current standard of care induced pneumonitis and fibrosis are reported. The pulmonary involvement in Hodgkin lymphoma may cause differential diagnostic difficulty. Lung involvement could modify stage and consequently treatment, and the development of side effects might determine later quality of life and expected lifetime. Therefore, identification of lung involvement is crucial.

Entities:  

Keywords:  Hodgkin lymphoma; Hodgkin-lymphoma; bleomycin; chest irradiation; lung involvement; mellkasi irradiáció; második daganat; second tumor; tüdőérintettség

Mesh:

Substances:

Year:  2016        PMID: 26801361     DOI: 10.1556/650.2016.30351

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  2 in total

1.  Clinical and misdiagnosed analysis of primary pulmonary lymphoma: a retrospective study.

Authors:  D Yao; L Zhang; P L Wu; X L Gu; Y F Chen; L X Wang; X Y Huang
Journal:  BMC Cancer       Date:  2018-03-12       Impact factor: 4.430

2.  Nodular Sclerosing Hodgkin Lymphoma Combined with Disseminated Talaromyces marneffei Infection: A Case Report.

Authors:  Zhenming Yang; Wen Zeng; Ye Qiu; Guangnan Liu; Jianquan Zhang
Journal:  Infect Drug Resist       Date:  2021-12-24       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.